Trial Profile
Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs CTL 119 (Primary) ; MTV-273 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- 28 Jun 2021 Planned End Date changed from 9 May 2036 to 1 Mar 2036.
- 28 Jun 2021 Planned primary completion date changed from 9 May 2022 to 1 Mar 2036.
- 27 May 2021 Planned primary completion date changed from 9 May 2021 to 9 May 2022.